Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesLaboratory/PathologyAetna lipid screening coverage update | OpenPayer
    Ask Trek AI about this page
    CurrentAetnaPolicy 0525

    Screening for Lipid Disorders

    Customize your policy alerts

    Sign up for Aetna Policy 0525 alerts

    Get alerted when Policy 0525 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Defines Aetna's coverage stance for laboratory screening tests for lipid disorders (cholesterol, HDL, LDL, triglycerides, and related direct measurements) and identifies investigational tests; applies to members under Aetna plans and to ordering providers seeking coverage determinations.

    Policy Summary
    PayerAetna
    PolicyScreening for Lipid Disorders
    Policy CodePolicy 0525
    Change TypeNo material change
    Effective DateJun 15, 2001
    Last ReviewJul 14, 2023
    Next Review DateMay 23, 2024
    Key ActionDocument medical necessity when ordering diagnostic cholesterol testing and select appropriate CPT/ICD-10 codes.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    3Medically necessary tests

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    4Experimental/investigational
    5Key CPT codes
    5 yrsAdult screening interval

    Coverage Criteria

    Medically Necessary

    Aetna considers the following medically necessary:

    Medically necessary lipid tests: 1) Directly measured low-density lipoprotein cholesterol (LDL-C) in persons with triglyceride levels greater than 250 mg/dL and in persons with type 2 diabetes; 2) Measurement of serum triglycerides for screening and diagnosis of lipid abnormalities; 3) Total serum cholesterol and high-density lipoprotein cholesterol (HDL-C) screening for screening and diagnosis of lipid abnormalities.

    From Aetna policy medical necessity section

    Experimental / Investigational

    The following are considered experimental and investigational:

    Experimental/investigational tests: Breath isoprene measurements for screening or monitoring; cholesterol skin testing to predict coronary heart disease risk; directly measured LDL-C in persons without type 2 diabetes or hypertriglyceridemia; direct measurement of very low-density lipoprotein (VLDL) cholesterol.

    Listed as experimental/investigational in policy

    Covered when supported by evidence

    Key evidence-based conclusions and implications:

    LDL particle testing conclusion: Lipoprotein particle measures (ApoB/ApoA-I, LDL-P/HDL-P) marginally improved net reclassification but did not improve c-statistics; associations attenuate after adjustment for standard lipids, indicating limited incremental prognostic benefit over the standard lipid panel.

    From systematic reviews and UpToDate summary

    Pediatric screening evidence: Evidence for universal screening in children/adolescents is limited: simulated diagnostic yield for elevated total cholesterol varies by age and BMI (estimated 4.8%–12.3% in one synthesis); diagnostic yield for familial hypercholesterolemia (FH) from universal childhood screening is 1.3–4.8 per 1,000 screened. Randomized and observational studies show modest short-term lipid improvements with dietary counseling and short-term LDL-C reductions with lipid-lowering drugs, but long-term adult outcome benefits are unproven.

    USPSTF evidence reviews and systematic trial summaries

    FH cascade testing: Cascade testing in relatives of index FH cases is cost-effective; combination contact strategies may increase relative testing response with a median of approximately 1 new relative identified per index case.

    Cholesterol screening of asymptomatic persons is governed by member plan preventive benefits. Cholesterol screening of asymptomatic persons is not covered for members whose plans do not provide coverage for preventive services. Diagnostic cholesterol testing, however, remains covered when medically necessary regardless of whether a member’s plan covers preventive services; check benefit plan descriptions for specifics.

    Evidence for universal childhood screening for familial hypercholesterolemia (FH) is limited with respect to long-term clinical outcomes. Systematic reviews found a diagnostic yield of approximately 1.3–4.8 cases per 1,000 screened, but there is no eligible evidence demonstrating that childhood screening for FH affects myocardial infarction or stroke in adulthood. Short-term trials document LDL-C reductions with lipid-lowering therapy in children, but long-term benefits and harms of initiating such therapy in childhood are not established.

    Direct measurement of LDL-C and VLDL-C has specific, limited indications. Aetna considers directly measured LDL-C medically necessary for persons with triglyceride levels greater than 250 mg/dL and for persons with type 2 diabetes, and guidance suggests direct LDL is recommended when triglycerides exceed 400 mg/dL and considered in the 250–400 mg/dL range. By contrast, direct measurement of VLDL cholesterol (CPT 83719) is considered experimental/investigational and not covered.

    Lipoprotein particle testing (for example, ApoB/ApoA‑I and LDL‑P/HDL‑P) has been studied for incremental risk prediction but does not demonstrate clear added prognostic value over the standard lipid panel. Systematic reviews and guideline summaries report only marginal improvements in reclassification and consistently note null findings for the c‑statistic; associations attenuate after adjustment for standard lipid measures. Therefore, routine use of lipoprotein particle testing for cardiovascular risk assessment in asymptomatic adults is not supported.

    Covered Indications

    Direct LDL-C measurement

    Direct LDL-C measurement is covered when selection criteria are met:

    Covered indications for direct LDL-C (83721): A) Directly measured LDL-C is covered for persons with triglyceride levels greater than 250 mg/dL; B) Directly measured LDL-C is covered for persons with type 2 diabetes.>250 mg/dL

    Policy states direct LDL-C preferred/covered for TG >250 mg/dL and preferred assay in type 2 diabetes

    Recommendation for very high triglycerides: Direct measurement of LDL-C is recommended (preferred) when triglyceride levels are greater than 400 mg/dL because calculated LDL-C may be inaccurate at that level.>400 mg/dL

    NCEP guidance referenced in policy background

    Serum triglyceride measurement

    Serum triglyceride measurement is covered for the following purposes:

    Coding

    Covered CPT Codes (when selection criteria met) and CPTs referencedCPT
    80061Lipid panel
    82465Cholesterol, serum or whole blood, total
    83718Lipoprotein, direct measurement; high density cholesterol (HDL cholesterol)
    84478Triglycerides
    83721Lipoprotein, direct measurement; LDL cholesterol
    83719Lipoprotein, direct measurement; VLDL cholesterol
    ICD-10 Codes referencedICD-10
    E78.1Pure hyperglyceridemia
    E78.2Mixed hyperlipidemia
    Z13.220Encounter for screening for lipoid disorders
    E08.00-E13.9Diabetes mellitus
    Triglyceride thresholds for direct LDL consideration (per policy and NCEP)
    Preferred threshold> 250 mg/dL — direct LDL preferred (covered)
    Recommended threshold> 400 mg/dL — direct LDL recommended
    Intermediate range250–400 mg/dL — calculated LDL less accurate; consider direct LDL especially in type 2 diabetes

    Provider Actions / Notes

    Note

    Coverage tied to selection criteria

    Coverage for specific CPT/ICD codes is tied to the medical necessity and selection criteria in this policy. Certain codes (for example, direct LDL-C measurement CPT 83721 and lipid panel CPT 80061) are covered only when the member meets the documented clinical indications described in the policy (eg, triglycerides >250 mg/dL, type 2 diabetes, or diagnoses such as E78.1/E78.2). Verify that the ordering and diagnosis meet the policy criteria before submission.

    • Affected codes: CPT 80061, 82465, 83718, 84478, 83721 — covered only if selection criteria are met; CPT 83719 (VLDL) — not covered for listed indications; ICD-10: E78.1, E78.2, Z13.220, E08.00–E13.9 when criteria apply.
    Prior Authorization

    Prior Authorization / Plan Rules

    This policy provides clinical guidance; prior authorization (PA) requirements, specific PA codes, and operational PA processes are determined by the member’s benefit plan and/or administrative procedures. Providers should check payer-specific PA lists and obtain any required authorization prior to testing to avoid claim denials.

    • This CPB does not itself list PA codes or replace plan-level PA rules.

    Ordering Requirements

    Billing Rule

    ORDERING: select correct codes and document medical necessity

    Ordering clinicians must select the appropriate CPT and ICD-10 codes and document medical necessity when requesting lipid testing; diagnostic testing requires supporting documentation.

    • Ensure the chosen CPT codes reflect the tests ordered (examples: 80061, 82465, 83718, 84478, 83721).
    • Provide clinical rationale in the record to demonstrate that testing meets policy medical necessity criteria.
    Note

    ORDERING for cascade testing: require confirmed index case

    Before initiating cascade testing of relatives, confirm that the index case has FH genetically confirmed or a definitive clinical diagnosis and document this in the clinical record.

    • Do not proceed with relative cascade testing without documented genetic confirmation or definitive clinical diagnosis of the index case.

    Not Covered / Experimental

    Breath isoprene measurement and cholesterol skin testing remain investigational. Breath isoprene analysis is under development, has unresolved technical and standardization issues, and has not been adopted as a routine clinical method. For these reasons, breath isoprene measurements and cholesterol skin testing are considered experimental/investigational and are not covered for screening or monitoring of lipid disorders.

    Direct measurement of very low‑density lipoprotein (VLDL) cholesterol using CPT 83719 is specifically addressed in the coding and policy sections and is considered experimental/investigational and not covered.

    Routine ordering of LDL particle or subfraction testing as an alternative to the standard lipid panel is not supported by the evidence cited in this policy. Studies show limited incremental predictive value beyond standard lipid measures, with no consistent improvement in c‑statistics; consequently, routine LDL particle/subfraction testing is not covered as a substitute for standard lipid panels.

    Frequency Limits

    Total cholesterol/HDL and lipid panel — guideline-based screening interval
    Guideline interval (average-risk adults)Approximately every 5 years for total cholesterol and HDL-C screening
    Longer intervalsLonger intervals may be reasonable in low-risk subjects with previously desirable cholesterol levels
    High-risk individualsScreening frequency left to clinical discretion for persons with major CHD risk factors
    Lipid measurement — suggested interval
    Suggested interval (general)Every 3–5 years for lipid measurement depending on prior values and risk
    If clearly below treatment thresholdRepeat every 5 years

    Definitions

    Calculated VLDL (NCEP guidance)
    VLDL calculation formulaVLDL = total triglycerides / 5 (per NCEP)
    RationaleCalculated VLDL considered sufficiently accurate by NCEP
    ContextUsed when estimating VLDL from fasting triglyceride measurement
    Direct LDL-C indications and clinical situations
    Primary recommendationDirect LDL-C measurement recommended when triglycerides > 400 mg/dL
    Consider direct LDLConsider direct LDL when triglycerides are 250–400 mg/dL because calculated LDL is less accurate
    Type 2 diabetes

    Background

    Serum cholesterol levels correlate with future cardiovascular risk, and multiple guideline bodies provide varying age‑ and risk‑based screening recommendations. For average‑risk adults, guideline summaries generally recommend lipid screening at intervals of about every 5 years. Additionally, clinical guidance notes repeating lipid measurements every 3–5 years depending on proximity to treatment thresholds and prior values.

    Revision History

    2023-07-14last_reviewLatest

    Policy was last reviewed on 07/14/2023.

    2001-06-15effective

    Policy effective date established as 06/15/2001.

    2024-05-23next_review

    Next scheduled policy review set for 05/23/2024.

    Policy Summary
    PayerAetna
    PolicyScreening for Lipid Disorders
    Policy CodePolicy 0525
    Change TypeNo material change
    Effective DateJun 15, 2001
    Last ReviewJul 14, 2023
    Next Review DateMay 23, 2024
    Key ActionDocument medical necessity when ordering diagnostic cholesterol testing and select appropriate CPT/ICD-10 codes.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsCodingProvider Actions / NotesOrdering RequirementsNot Covered / ExperimentalFrequency LimitsDefinitionsBackgroundRevision History

    Systematic review of cascade strategies

    Screening and diagnosis: Measurement of serum triglycerides is covered for screening and diagnosis of lipid abnormalities.

    Listed as medically necessary in policy

    Role in risk assessment: The NCEP and guideline bodies recommend measurement of triglyceride levels as part of lipid assessment; calculated VLDL (triglycerides/5) may be used per NCEP guidance.

    Background guidance supports triglyceride measurement and calculated VLDL

    Total cholesterol and HDL-C

    Total cholesterol and HDL-C are covered for screening and diagnosis with guideline-based periodicity:

    Covered tests: Total serum cholesterol and high-density lipoprotein cholesterol (HDL-C) screening are covered for screening and diagnosis of lipid abnormalities.

    From Aetna medical necessity statements

    Suggested screening interval (adults): Guideline summaries (USPSTF and others) suggest periodic screening; an interval of approximately every 5 years is recommended for average-risk adults, with shorter intervals (e.g., every 3 years) considered for those near or above treatment thresholds.5 years; 3 years when near/above threshold

    USPSTF and UpToDate guidance cited in background

    Pediatric/adolescent screening for multifactorial dyslipidemia or familial hypercholesterolemia when clinically indicated

    Screening children and adolescents is covered when clinically indicated; diagnostic yield depends on age and BMI:

    Multifactorial dyslipidemia screening yield: Simulated diagnostic yield for elevated total cholesterol in children varies by age and BMI and has been estimated between approximately 4.8% and 12.3% (higher in obese children and at ages when total cholesterol peaks).

    USPSTF evidence synthesis

    Familial hypercholesterolemia screening yield: Universal childhood screening for familial hypercholesterolemia yields an estimated 1.3 to 4.8 cases per 1,000 screened; evidence on long-term clinical benefits of childhood screening and treatment is lacking.1.3–4.8 per 1,000

    USPSTF evidence synthesis

    Clinical indication requirement: Screening in children/adolescents should be performed when clinically indicated (e.g., family history suggestive of hyperlipidemia or other risk factors); benefits and harms should be considered given limited long-term outcome data.

    Policy and evidence-based guidance

  1. Confirm PA requirements via provider portal or plan documents before ordering.
  2. Denial Risk

    Coverage decision note

    Coverage determinations are benefit- and contract-specific. The presence of a clinical policy bulletin does not guarantee coverage for a particular member — benefits, limitations, exclusions, and plan-level preventive coverage provisions govern final decisions.

    • Check the member’s benefit plan for preventive service coverage; diagnostic testing may be covered separately when medically necessary.
    • Clinical policy bulletins are guidance documents and must be applied in the context of contract terms.
    Documentation Required

    Documentation for cascade testing

    For cascade testing programs targeting familial hypercholesterolemia (FH), index cases should have genetic confirmation or a definitive clinical diagnosis documented in the medical record before relatives are enrolled in cascade testing. Maintain records of the index case’s diagnostic evidence and the outreach/testing of relatives per program protocols.

    • Document genetic confirmation or definitive clinical diagnosis for index cases before cascade testing.
    • Record numbers of relatives eligible, contacted, tested, and confirmed to have FH as recommended in studies and guidelines.
    Note

    Therapy context

    Treatment context: There are evidence summaries supporting therapy for identified lipid disorders (eg, statins, bile acid sequestrants, ezetimibe) but no step-therapy rules are specified in this policy. Providers should follow current clinical guidelines for treatment once diagnosis is established; this policy does not impose step therapy requirements.

    • Evidence shows LDL-C reductions with statins and other agents in trials referenced in the background.
    • No step-therapy or sequencing mandates are included in this CPB; follow applicable plan or guideline requirements for therapeutic management.
  3. Record the index case confirmation method and maintain documentation for program evaluation (numbers eligible, contacted, tested, confirmed).
  4. If near/above treatment thresholdRepeat every 3 years
    Direct LDL should be considered as the preferred LDL assay in persons with type 2 diabetes due to high rate of hypertriglyceridemia
    LDL-P — low-density lipoprotein particle testing
    DefinitionLDL-P: low-density lipoprotein particle testing measuring lipoprotein particle numbers and subfractions
    Clinical utilityMay marginally improve reclassification but does not improve c-statistics versus standard lipids
    LimitationsAssociations attenuate after adjustment for standard lipids, indicating limited incremental prognostic value
    Familial hypercholesterolemia (FH) — definition and diagnostic approaches
    DefinitionFamilial hypercholesterolemia (FH): an inherited condition causing very high LDL-C from birth associated with premature cardiovascular disease
    Diagnosis approachesDiagnosed clinically or by genetic testing; cascade testing programs should use genetically confirmed index cases or definitive clinical diagnosis
    Screening yieldDiagnostic yield of universal childhood FH screening estimated at about 1.3–4.8 cases per 1,000 screened